The present invention relates to compounds as defined herein, which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to therapies using these activators. In particular, the invention relates to these activator compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3′,5′-adenosine monophosphate (cAMP).
[EN] COMPOUNDS AND THEIR USE AS PDE4 ACTIVATORS<br/>[FR] COMPOSÉS ET LEUR UTILISATION EN TANT QU'ACTIVATEURS DE PDE4
申请人:MIRONID LTD
公开号:WO2019193342A1
公开(公告)日:2019-10-10
The present invention relates to compounds as defined herein, which are activators of long form cyclic nucleotide phosphodiesterase-4 (PDE4) enzymes (isoforms) and to therapies using these activators. In particular, the invention relates to these activator compounds for use in a method for the treatment or prevention of disorders requiring a reduction of second messenger responses mediated by cyclic 3',5-adenosine monophosphate (cAMP).
Catalytic Enantioselective Borane Reduction of Benzyl Oximes: Preparation of (<i>S</i>)-1-Pyridin-3-yl-ethylamine bis Hydrochloride